2020
DOI: 10.1038/s41586-020-2456-9
|View full text |Cite
|
Sign up to set email alerts
|

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Abstract: During the coronavirus disease-2019 (COVID-19) pandemic, severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) has led to the infection of millions of people and has claimed hundreds of thousands of lives. The entry of the virus into cells depends on the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2. Although there is currently no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-2… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

265
2,651
11
21

Year Published

2020
2020
2023
2023

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 1,917 publications
(2,998 citation statements)
references
References 50 publications
265
2,651
11
21
Order By: Relevance
“…Next, we evaluated 15 human mAbs that were identified by sorting of individual SARS-CoV-2 RBD-binding B-cells (Robbiani et al, 2020). The panel was selected on the basis of neutralization potency using the HIV-1 NL ΔEnv-NanoLuc assay, and all had IC 50 values ranging between 3 and 60 ng/ml in this assay.…”
Section: Construction Of a Replication-competent Vsv/sars-cov2 Chimermentioning
confidence: 99%
See 1 more Smart Citation
“…Next, we evaluated 15 human mAbs that were identified by sorting of individual SARS-CoV-2 RBD-binding B-cells (Robbiani et al, 2020). The panel was selected on the basis of neutralization potency using the HIV-1 NL ΔEnv-NanoLuc assay, and all had IC 50 values ranging between 3 and 60 ng/ml in this assay.…”
Section: Construction Of a Replication-competent Vsv/sars-cov2 Chimermentioning
confidence: 99%
“…The human plasma and mAbs used in this study were previously reported (Robbiani et al, 2020). The human samples were obtained at the Rockefeller University Hospital under protocols approved by the university's institutional review board.…”
Section: Human Plasma Samples and Mabsmentioning
confidence: 99%
“…Our study has several limitations. First, we used a single S1-protein speci c ELISA assay, which does not re ect the full array of anti SARS-CoV-2 antibody formation and the functional neutralizing activity (6). Additionally, we did not address the individual kinetics of antibody response, as patients were tested at a single time point within one month from the time of diagnosis (which also differs to a variable extent from the time of disease onset), rather than longitudinally.…”
Section: Discussionmentioning
confidence: 99%
“…SARS-CoV-2 antibody detection assays are currently developed at a rapid pace. Serological studies should enhance the understanding of the immune response to SARS-CoV-2 (6), allow the diagnosis of recent or past infection (when RT-PCR was not performed or was false-negative) (7,8), support population-based studies and public-health strategies, and inform vaccine development. Additionally, SARS-CoV-2 IgG detection allows for the initial screening of immune-donor plasma -recently shown to be a promising therapeutic approach in critically ill COVID-19 patients (9).…”
Section: Introductionmentioning
confidence: 99%
“…Plasma collected from patients who have recovered from a SARS-CoV-2 infection can contain antiviral antibodies detectable through serological testing 2 . It is unclear to what extent these antibodies provide anti-viral protection, but at least a subset of patients presents with high titres of neutralizing antibodies, or with speci c potent antibodies irrespective of the titre 3 . Passing on this plasma to patients newly diagnosed with SARS-CoV-2 infection might help them to clear the infection more rapidly, as it could provide them with passive polyclonal antibodies and thus reduce the antiviral load.…”
Section: Background and Rationale {6a}mentioning
confidence: 99%